Haemonetics Second Quarter 2025 Earnings: EPS Misses Expectations

Haemonetics (NYSE:HAE) Second Quarter 2025 Results

Key Financial Results

• Revenue: US$345.5m (up 8.6% from 2Q 2024).
• Net income: US$33.8m (up 36% from 2Q 2024).
• Profit margin: 9.8% (up from 7.8% in 2Q 2024).
• EPS: US$0.67 (up from US$0.49 in 2Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Haemonetics EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 14%.

Looking ahead, revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 22% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Haemonetics (including 1 which doesn't sit too well with us).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.